RT Book, Section
A1 T. Desman, Garrett
A1 Donovan, Michael
A2 Barnhill, Raymond L.
A2 Crowson, A. Neil
A2 Magro, Cynthia M.
A2 Piepkorn, Michael W.
A2 Kutzner, Heinz
A2 Desman, Garrett T.
SR Print(0)
ID 1178397989
T1 Current and Emerging Molecular Technologies in Dermatopathology
T2 Barnhill's Dermatopathology, 4e
YR 2020
FD 2020
PB McGraw Hill Education
PP New York, NY
SN 9780071828222
LK dermatology.mhmedical.com/content.aspx?aid=1178397989
RD 2024/04/19
AB Since  Rudolph  Virchow  first  applied  the  light  microscope  to  the  analysis  of  tissues,  traditional  histopathological  assessment  of  cutaneous  diseases  has  largely  remained  unchanged  over  the  past  150  years.1  The  process  of  immunohistochemistry  was  invented  in  the  1940s  by  Coons,  Creech,  and  Jones  and  revolutionized  the  pathologist’s  ability  to  identify  cellular  protein  expression  and  the  subclassification  of  tumors  by  various  lines  of  differentiation.  With  the  launch  of  the  Human  Genome  Project  in  1990,  scientists  were  able  to  map  all  of  the  genes  of  the  human  genome  from  both  a  physical  and  functional  standpoint.2  Since  then,  an  explosion  of  data  has  been  derived  from  genomic,  epigenomic,  transcriptomic,  proteomic,  lipidomic,  and  metabolomic  (“omics”)  technologies.3  Below,  we  briefly  summarize  the  role  of  some  of  these  technologies  in  the  current  and  future  practice  of  dermatopathology  (Table  A2-1).